(Q33346715)

26 July 2017

title

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma (English)

1 reference

26 July 2017

1 reference

0 references

1 reference

10

W Boogerd

0 references

author name string

G C de Gast

1

1 reference

26 July 2017

D Batchelor

2

1 reference

26 July 2017

M J Kersten

3

1 reference

26 July 2017

F A Vyth-Dreese

4

1 reference

26 July 2017

J Sein

5

1 reference

26 July 2017

W F van de Kasteele

6

1 reference

26 July 2017

W J Nooijen

7

1 reference

26 July 2017

O E Nieweg

8

1 reference

26 July 2017

M A de Waal

9

1 reference

26 July 2017

W Boogerd

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

88

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

175-180

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600717

26 July 2017

exact match

0 references

cites work

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Prognostic factors in metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377058

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600717

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600717

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600717

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600717

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12610499

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12610499

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12610499

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6600717

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference